<div id="readability-page-1"><div>Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026 2026 marks highest healthcare cost increase in more than a decade, as GLP-1 drugs and AI-enabled billing emerge as new drivers Milliman, Inc., the premier global consulting and actuarial firm, today announced the release of the 2026 Milliman Medical Index (MMI), which measures healthcare costs for Americans covered by a typical employer-sponsored health insurance plan. Healthcare costs for the average person rose 7.9% in 2026 to $8,460—the highest annual increase in more than a decade, excluding pandemic-era fluctuations. Healthcare costs for the MMI’s hypothetical family of four reached $37,824. Outpatient facility costs rose 7.5% and pharmacy costs rose 14.8%, with those two service categories accounting for 69% of the total year-over-year increase. &#34;Pharmacy costs have been a persistent driver of healthcare cost growth for several years now, but 2026 represents an acceleration of the trend,&#34; says Milliman Principal and Consulting Actuary Andrew Timcheck. &#34;A 14.8% increase in pharmacy costs—driven by GLP-1 utilization and high-cost specialty drugs—combined with continued outpatient facility cost growth, puts the 2026 trend environment in a category of its own for this decade.&#34; &#34;The 7.9% increase we are seeing this year is not the result of a single acute shock—it reflects structural forces that are not going away,&#34; says Milliman Principal and Consulting Actuary Deana Bell. &#34;Outpatient costs have quadrupled for the MMI’s family of four since the MMI was first published in 2005, with much of the trend exacerbated by delivery system consolidation, specialty drug growth, and site-of-care shifts.” &#34;For the first time in the MMI's history, we're flagging artificial intelligence as a factor in healthcare cost trends,&#34; says Milliman Principal and Consulting Actuary Jason Clarkson. &#34;Hospitals are using AI to optimize their billing and claim coding, and payers are using it to enhance their claim adjudication processes, especially for detecting fraud, waste, and abuse. That dynamic is worth watching as costs hit their highest growth rate in over a decade.&#34; To read the 2026 Milliman Medical Index, visit milliman.com/en/insight/2026-milliman-medical-index. About Milliman Milliman leverages deep expertise, actuarial rigor, and advanced technology to develop solutions for a world at risk. We help clients in the public and private sectors navigate urgent, complex challenges—from extreme weather and market volatility to financial insecurity and rising health costs—so they can meet their business, financial, and social objectives. Our solutions encompass insurance, financial services, healthcare, life sciences, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. Visit us at milliman.com. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MjAxMTAzNjRyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MjAxMTAzNjRyMQ"/> Jeremy Engdahl-Johnson Milliman, Inc. Tel: +1 646.473.3021 Jeremy.engdahl-johnson@milliman.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260520110364/en/</div></div>

礼来

诺和诺德公司

基因改革 ETF - ARK

2026 年 Milliman 医疗指数显示，平均美国家庭的医疗费用已达到 37,824 美元，增长了 7.9%，是十多年来的最高水平。主要驱动因素包括药品费用上涨 14.8%，受 GLP-1 药物的影响，以及门诊设施费用上涨 7.5%。报告强调了人工智能在优化账单流程中的作用，这对这一显著的成本增长起到了推动作用

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

- 2026 年，典型美国家庭医疗成本达 37,824 美元，年增长 7.9%。  
- 药房费用增长 14.8%，门诊费用增长 7.5%，合计占总增长的 69%。  
- 人工智能首次被标记为医疗成本趋势因素。

MorningStar

标普医疗保健服务 ETF - SPDR

标普全球医疗股指数 ETF - iShares

2 倍做多 LLY ETF - Defiance

动态生物技术与基因组 ETF - Invesco

2 倍做多 LLY ETF - Direxion

1 倍做空 LLY ETF - Direxion

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

2 倍做多 NVO ETF - Defiance

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普制药指数 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - Vanguard

美国制药 ETF - iShares

Milliman 医疗指数显示，美国一个家庭的医疗费用将在 2026 年达到 37,824 美元